Skip to main content

Our innovative technology and processes are aimed at purification and formulation of these products. Pharming has operations in the Netherlands, Germany, France and the US, with its headquarters in Leiden (NL).

Our lead product, RUCONEST®, is a recombinant human C1 inhibitor approved for the treatment of hereditary angioedema (HAE) attacks in the US, all 28 EU countries, Norway, Iceland, Liechtenstein, Israel, and South Korea. 

We are continuously looking for highly talented and motivated individuals from the (biotechnology) industry to join our team.

Please take a look at our vacancies or send us an open application. We look forward to receiving your CV and motivation letter. 

If you have any further questions regarding vacancies, or about working at Pharming in general, please contact our Recruitment Department:

Cookies: This website uses cookies Check the cookies page for more information Accept Decline